BRUSSELS Aug 27 Belgian biotech firm Ablynx burnt through more cash in the first half of 2015, as it increased spending on research and clinical trials for its experimental drugs.
The group, which makes treatments based on nanobodies, small antibodies found in llamas and alpacas, said it used up 35 million euros ($39.7 million) of cash in the first half of 2015.
16:38 Swift Energy completes $40 million sale of Louisiana asset10
03:00 Carrier incentives stir debate over 'rewarding' offshoring14
21:23 Princess Cruises to pay record-breaking criminal fine for ocean pollution16
15:41 U.N. imposes new sanctions on North Korea to slash cash from exports13